082800 — Vivozon Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- KR₩331bn
- KR₩360bn
- KR₩88bn
- 21
- 15
- 48
- 14
Annual income statement for Vivozon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 43,592 | 57,730 | 51,564 | 71,318 | 87,601 |
| Cost of Revenue | |||||
| Gross Profit | 7,130 | 19,664 | 21,437 | 31,321 | 45,407 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 63,888 | 111,738 | 62,346 | 68,762 | 85,802 |
| Operating Profit | -20,296 | -54,009 | -10,782 | 2,556 | 1,799 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -43,822 | -75,848 | -25,342 | -2,158 | -10,543 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -44,085 | -71,015 | -26,851 | -2,214 | -10,666 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -43,754 | -69,457 | -39,906 | -3,357 | -9,982 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -43,754 | -69,457 | -39,906 | -3,357 | -9,982 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,365 | -1,411 | -518 | -37.9 | -210 |
| Dividends per Share |